The Effects of Atorvastatin Calcium on Vascular Endothelial Function of Patients with Carotid Artery Plague_West China Medical Journal

Authors：

LIU Kunmei , DING Xiaojun , LIU Xiuyan , YANG En.

The Fourth People’s Hospital of Chengdu, Chengdu, Sichuan 610016, P. R. China;

Corresponding author：

Keywords：

阿托伐他汀钙; 颈动脉粥样硬化斑块; 血管内皮功能; 斑块逆转

DOI：

10.7507/1002-0179.20130007

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　探讨阿托伐他汀钙对颈动脉粥样硬化患者血管内皮的保护作用。方法　选取2010年10月－2011年8月颈动脉粥样硬化患者80例，随机分为治疗组和对照组。对照组给予阿司匹林肠溶片0.1 g，早饭后口服1次；治疗组在此基础上给予阿托伐他汀钙20 mg，每晚口服1次，10个月为1个疗程。分别在治疗前后进行颈动脉彩色多普勒超声检测颈动脉中膜厚度及颈动脉粥样硬化斑块面积，测定甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、一氧化氮（NO）、血管内皮素-1（ET-1）水平。两组患者在1个疗程治疗结束后停药12周，测定TG、TCH、LDL-C、HDL-C、NO、ET-1水平。结果　与治疗前比较，治疗组患者的TG、TC、LDL-C、ET-1水平显著降低，HDL-C、NO水平显著升高（P＜0.01）。颈动脉中膜厚度和颈动脉粥样硬化斑块面积明显变小（P＜0.05）。对照组无明显变化。治疗组停药12周后与停药时比较，TG、TC、LDL-C、ET-1水平显著升高，HDL-C、NO水平明显降低（P ＜0.05）。对照组无明显变化。结论　阿托伐他汀钙能显著改善颈动脉粥样硬化斑块患者的血管内皮功能、血脂水平，稳定颈动脉粥样硬化斑块，促进斑块逆转，且需要长期坚持服用。

Citation： LIU Kunmei,DING Xiaojun,LIU Xiuyan,YANG En.. The Effects of Atorvastatin Calcium on Vascular Endothelial Function of Patients with Carotid Artery Plague. West China Medical Journal, 2013, 28(1): 25-27. doi: 10.7507/1002-0179.20130007 Copy

1.	Henry JM, Barnett JP, Bennett M, et al. 卒中病理生理, 诊断及其治疗[M]. 高旭光，译. 3版. 沈阳: 辽宁科学技术出版社，2001: 13-15.
2.	Korybalska K, Kawka E, Breborowicz A, et al. Atorvastatin does not impair endothelial cell wound healing in an in vitro model of vascular injury[J]. J Physiol Pharmacol, 2012, 63(4): 389-395.
3.	他汀类药物预防缺血性卒中/短暂性脑缺血发作专家组. 他汀类药物预防缺血性卒中/短暂性脑缺血的专家建议[J]. 中华内科杂志, 2007, 46(1): 8l-82.
4.	van Schie RM, Verhoef TI, Boejharat SB, et al. Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose[J]. Drug Metabol Drug Interact, 2012, 27(4): 229-234.
5.	Barth JD. An update on carotid ultrasound measurement of intima-media thickness[J]. Am J Cardiol, 2002, 89(4A): 32B-38B.
6.	邹艳华, 戈晓华. 颈动脉超声多普勒实习手册[M]. 北京: 学苑出版社, 1996: 6-7.
7.	Kadoglou NP, Sailer N, Moumtzouoglou A, et al. Adipokines: a novel link between adiposity and carotid plaque vulnerability[J]. Eur J Clin Invest, 2012, 42(12): 1278-1286.
8.	Grundy SM，Cleeman JI，Merz CN，et al．Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ guidelines[J].Circulation, 2004, 110 (2): 227-239.
9.	Bo?entowicz-Wikarek M, Koce?ak P, Smertka M, et al. Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis-guidelines vs. reality[J]. Pharmacol Rep, 2012, 64(2): 377-385.
10.	Pramanik S, Das AK, Chakrabarty M, et al. Efficacy of alternate-day versus everyday dosing of atorvastatin[J]. Indian J Pharmacol, 2012, 44(3): 362-365.
11.	Kitamura A, Iso H, Imano H，et al. Carotid intima-media thickness and plaque characteristics as a risk factor for stroke in Japanese elderly men[J]. Stroke, 2004, 35(12): 2788-2794.
12.	Eussen SR, Rompelberg CJ, Klungel OH, et al. Modeling approach to simulate reductions in LDL cholesterol levels after combined intake of statins and phytosterols/-stanols in humans[J]. Lipids Health Dis, 2011,10: 187.

1. 　Henry JM, Barnett JP, Bennett M, et al. 卒中病理生理, 诊断及其治疗[M]. 高旭光，译. 3版. 沈阳: 辽宁科学技术出版社，2001: 13-15.
2. 　Korybalska K, Kawka E, Breborowicz A, et al. Atorvastatin does not impair endothelial cell wound healing in an in vitro model of vascular injury[J]. J Physiol Pharmacol, 2012, 63(4): 389-395.
3. 　他汀类药物预防缺血性卒中/短暂性脑缺血发作专家组. 他汀类药物预防缺血性卒中/短暂性脑缺血的专家建议[J]. 中华内科杂志, 2007, 46(1): 8l-82.
4. 　van Schie RM, Verhoef TI, Boejharat SB, et al. Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose[J]. Drug Metabol Drug Interact, 2012, 27(4): 229-234.
5. 　Barth JD. An update on carotid ultrasound measurement of intima-media thickness[J]. Am J Cardiol, 2002, 89(4A): 32B-38B.
6. 　邹艳华, 戈晓华. 颈动脉超声多普勒实习手册[M]. 北京: 学苑出版社, 1996: 6-7.
7. 　Kadoglou NP, Sailer N, Moumtzouoglou A, et al. Adipokines: a novel link between adiposity and carotid plaque vulnerability[J]. Eur J Clin Invest, 2012, 42(12): 1278-1286.
8. 　Grundy SM，Cleeman JI，Merz CN，et al．Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ guidelines[J].Circulation, 2004, 110 (2): 227-239.
9. 　Bo?entowicz-Wikarek M, Koce?ak P, Smertka M, et al. Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis-guidelines vs. reality[J]. Pharmacol Rep, 2012, 64(2): 377-385.
10. 　Pramanik S, Das AK, Chakrabarty M, et al. Efficacy of alternate-day versus everyday dosing of atorvastatin[J]. Indian J Pharmacol, 2012, 44(3): 362-365.
11. 　Kitamura A, Iso H, Imano H，et al. Carotid intima-media thickness and plaque characteristics as a risk factor for stroke in Japanese elderly men[J]. Stroke, 2004, 35(12): 2788-2794.
12. 　Eussen SR, Rompelberg CJ, Klungel OH, et al. Modeling approach to simulate reductions in LDL cholesterol levels after combined intake of statins and phytosterols/-stanols in humans[J]. Lipids Health Dis, 2011,10: 187.

West China Medical Journal

The Effects of Atorvastatin Calcium on Vascular Endothelial Function of Patients with Carotid Artery Plague

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content